drugset / Trial / NCT05216120
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
Timeline
- Start
- 2022-06-14
- Primary completion
- 2024-08-31
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | 4.5 mg | — |